Category - Developments

Developments

Titan Pharma’s Probuphine implant to treat OUD continues to gain national media attention

Channel 8’s Daytime aired nationally an interview with two senior executives of Titan Pharmaceuticals (NASDAQ:TTNP) – Dane Hallberg, EVP and chief commercial officer, and Dr. Kate DeVarney, EVP and chief scientific...

April 26, 2019

Developments

Orchard Therapeutics doses first patient in cryopreserved gene therapy trial

Orchard Therapeutics (NASDAQ:ORTX) has dosed the first patient in a study evaluating a cryopreserved formulation of OTL-103, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of Wiskott...

April 25, 2019

Developments

Kane Biotech in sales representation pact with SLA Brands

Kane Biotech (TSXV:KNE) entered a strategic partnership with Schiaffino, Lasky, & Associates (SLA Brands) to exclusively represent Kane’s bluestem line of products to distributors and retailers in the U.S. market...

April 24, 2019

Developments

Akari reports positive initial results from Phase 2 bullous pemphigoid trial

Akari Therapeutics (NASDAQ:AKTX) reported positive results from the first three bullous pemphigoid (BP) patients in an ongoing Phase 2 clinical trial. BP is a severe orphan inflammatory skin disease characterized by...

April 23, 2019

Developments

Researchers develop potentially safer CAR-T treatment

Researchers at the University of Southern California’s (USC) Norris Comprehensive Cancer Center have designed a new type of CAR-T treatment that reduces the risk of cytokine release syndrome (CRS), a dangerous immune...

April 23, 2019

Developments

Alder BioPharma BLA for eptinezumab accepted by FDA

Alder BioPharma (NASDAQ:ALDR) BLA application for eptinezumab, a monoclonal antibody for the prevention of migraines, has been accepted by the FDA. Administered intravenously, eptinezumab targets and suppresses...

April 23, 2019

Developments

Autolus Therapeutics ALL treatment gets FDA orphan drug designation

Autolus Therapeutics’ (NASDAQ:AUTL) AUTO3 has received FDA orphan drug designation for the treatment of acute lymphoblastic leukemia (ALL). AUTO3 is a T-cell therapy produced by genetically modifying a patient’s own T...

April 23, 2019

Developments

Sensus Healthcare SRT shows 98.9% skin cancer cure rate in retrospective study

Sensus Healthcare’s (NASDAQ:SRTS) superficial radiation therapy (SRT) demonstrated a 98.9% skin cancer cure in a five-year retrospective study. Sensus’ SRT is a low-energy X-ray technology used to treat non-melanoma...

April 23, 2019

Developments

Catasys in OnTrak pact with Optima Health in Virginia

Catasys (NASDAQ:CATS) entered into an agreement with Optima Health to provide its OnTrak solution to eligible commercial members in Virginia, with a launch expected in the second quarter of 2019. Catasys applies...

April 23, 2019

Developments

IntelGenx to demonstrate oral films CDMO services at CPhI North America

IntelGenx (TSXV:IGX; OTCQX:IGXT) plans to demonstrate the capabilities of its contract development and manufacturing organization (CDMO) services and its VersaFilm and VetaFilm oral film technologies, at CPhI North...

April 23, 2019

Category - Developments

Subscribe